Cheviot Value Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Cheviot Value Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.61K	Buy	+5	New	+$2.56K	﹤0.01%	419

Other funds holding VRTX

Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $77.1B AUM 11.99% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $179B AUM 29.92% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Cheviot Value Management's VRTX Position: Q3 2026 in Review

Cheviot Value Management opened a new position in Vertex Pharmaceuticals (VRTX) in Q3 2026: 5 shares worth $2.61K. The stake represents ﹤0.01% of the portfolio and ranks #419 among its holdings.

1,304 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

Cheviot Value Management held 5 shares of Vertex Pharmaceuticals worth $2.61K as of Q3 2026.
Vertex Pharmaceuticals was a new Cheviot Value Management position in Q3 2026.
Vertex Pharmaceuticals made up ﹤0.01% of Cheviot Value Management's portfolio in Q3 2026, its #419 holding.
1,304 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Cheviot Value Management's 13F filing for Q3 2026, filed 9 Nov 2026.